Downloads: 131

Files in This Item:
File Description SizeFormat 
journal.pone.0136981.pdf1.24 MBAdobe PDFView/Open
Title: The anti-proliferative effect of boron neutron capture therapy in a prostate cancer xenograft model
Authors: Takahara, Kiyoshi
Inamoto, Teruo
Minami, Koichiro
Yoshikawa, Yuki
Takai, Tomoaki
Ibuki, Naokazu
Hirano, Hajime
Nomi, Hayahito
Kawabata, Shinji
Kiyama, Satoshi
Miyatake, Shin Ichi
Kuroiwa, Toshihiko
Suzuki, Minoru  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-5421-9417 (unconfirmed)
Kirihata, Mitsunori
Azuma, Haruhito
Author's alias: 鈴木, 実
Issue Date: 1-Sep-2015
Publisher: Public Library of Science
Journal title: PLOS ONE
Volume: 10
Issue: 9
Thesis number: e0136981
Abstract: [Purpose] Boron neutron capture therapy (BNCT) is a selective radiation treatment for tumors that preferentially accumulate drugs carrying the stable boron isotope, 10B. BNCT has been evaluated clinically as an alternative to conventional radiation therapy for the treatment of brain tumors, and more recently, recurrent advanced head and neck cancer. Here we investigated the effect of BNCT on prostate cancer (PCa) using an in vivo mouse xenograft model that we have developed. [Materials and Methods] Mice bearing the xenotransplanted androgen-independent human PCa cell line, PC3, were divided into four groups: Group 1: untreated controls; Group 2: Boronophenylalanine (BPA); Group 3: neutron; Group 4: BPA-mediated BNCT. We compared xenograft growth among these groups, and the body weight and any motility disturbance were recorded. Immunohistochemical (IHC) studies of the proliferation marker, Ki-67, and TUNEL staining were performed 9 weeks after treatment. [Results] The in vivo studies demonstrated that BPA-mediated BNCT significantly delayed tumor growth in comparison with the other groups, without any severe adverse events. There was a significant difference in the rate of freedom from gait abnormalities between the BPA-mediated BNCT group and the other groups. The IHC studies revealed that BNCT treatment significantly reduced the number of Ki-67-positive cells in comparison with the controls (mean±SD 6.9±1.5 vs 12.7±4.0, p<0.05), while there was no difference in the number of apoptotic cells, suggesting that BPA-mediated BNCT reduced PCa progression without affecting apoptosis at 9 weeks post-treatment. [Conclusions] This study has provided the first preclinical proof-of-principle data to indicate that BPA-mediated BNCT reduces the in vivo growth of PCa. Although further studies will be necessary, BNCT might be a novel potential treatment for PCa.
Rights: © 2015 Takahara et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
URI: http://hdl.handle.net/2433/214549
DOI(Published Version): 10.1371/journal.pone.0136981
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.